ArticleClinical pharmacology and therapeutics2026
Reducing Exposure Before Birth: An Interrupted Time Series Study of Prenatal Exposure to Fetotoxic Medications Under Risk Management Plans in Canada.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Pharmacology at the Point of Decision.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canada's 2009 risk management plan (RMP) framework has not been evaluated for prenatal exposure impact. Conversely, widely used drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) lack RMPs. We assessed first-trimester exposure to RMP-regulated medications following regulatory interventions and to NSAIDs following safety publications. We conducted interrupted time series analyses using data from the Québec Pregnancy Cohort (1998-2022), including pregnancies among individuals aged 15-45 years with continuous public prescription drug insurance. First-trimester exposure was defined as dispensed prescriptions overlapping or initiated during gestational weeks 0-14. Exposures included RMP-regulated medications (overall, retinoids, and valproic acid) and prescription NSAIDs. RMP dates served as interruption points. Monthly incidence rates were analyzed using segmented Poisson regression to estimate incidence rate ratios (IRRs) with 95% confidence intervals (CIs). Among 559,215 eligible pregnancies, 6,215 and 87,820 involved first-trimester exposure to RMP-regulated medications and NSAIDs, respectively. The Canadian RMP framework was associated with an immediate 45.3% reduction (IRR: 0.547, 95% CI: 0.403-0.743) and a sustained 1.3% monthly decline (IRR: 0.987, 95% CI: 0.981-0.994). Retinoid exposure declined by 12.5% per month post-SMART RMP (IRR: 0.875, 95% CI: 0.772-0.993), with reductions post-iPLEDGE RMP (IRR: 0.949, 95% CI: 0.932-0.966). Valproic acid exposure declined after the strengthened FDA boxed warning (IRR: 0.869, 95% CI: 0.836-0.903) and migraine prophylaxis contraindication (IRR: 0.754, 95% CI: 0.543-1.046). NSAID publications yielded transient effects. RMPs were associated with sustained prenatal exposure reductions, whereas safety publications were associated with transient effects, highlighting the need for reinforced risk-management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.